BioXcel Therapeutics, Inc. — Director's Dealing 2023

Jun 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2023-06-14

Reporting Person: Mehta Vimal (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-14	Common Stock	M	2609	—	Acquired	39903	Direct
2023-06-15	Common Stock	M	30000	$0.41	Acquired	69903	Direct
2023-06-15	Common Stock	S	21988	$21.41	Disposed	47915	Direct
2023-06-15	Common Stock	S	8012	$21.90	Disposed	39903	Direct
2023-06-16	Common Stock	M	30000	$0.41	Acquired	69903	Direct
2023-06-16	Common Stock	S	24987	$20.01	Disposed	44916	Direct
2023-06-16	Common Stock	S	4266	$20.90	Disposed	40650	Direct
2023-06-16	Common Stock	S	747	$21.89	Disposed	39903	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-14	Restricted Stock Units	$	M	2609	Disposed		Common Stock (2609)	Direct
2023-06-15	Stock Option (Right to Buy)	$0.41	M	30000	Disposed	2027-08-23	Common Stock (30000)	Direct
2023-06-16	Stock Option (Right to Buy)	$0.41	M	30000	Disposed	2027-08-23	Common Stock (30000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2000	Indirect

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.83 to $21.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.83 to $22.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.57 to $20.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.59 to $21.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7: On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

F8: The option is fully vested and exercisable.